<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39274232</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>17</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Symptoms, Course, and Factors Related to Long-Term Morbidity, Including Differences between Infection Strains, in Patients with Long COVID in a Primary Care Clinic in Japan: An Observational Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5019</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13175019</ELocationID><Abstract><AbstractText><b>Objectives:</b> The objectives were to investigate the clinical characteristics and course of long COVID, defined as the persistence of symptoms at least one month after the onset of COVID-19, in outpatients and to clarify differences in symptoms between SARS CoV-2 mutant strains. <b>Methods:</b> Our observational study in a primary care institution in Japan included 1053 patients with long COVID who visited our outpatient clinic between April 2021 and March 2023. Symptom distribution, performance status, and patient background at the time of the first outpatient visit were compared between infectious strains (Delta and before group and Omicron group). Background factors and symptoms related to time to remission were also analyzed. <b>Results:</b> The severity of COVID-19 in the acute phase was mild, moderate, and severe in 82.2%, 14.9%, and 2.9% in the Delta and before group; and in 97.6%, 1.7%, and 0.4% in the Omicron group, respectively. Vaccination coverage was significantly different between the Delta and before (37.1%) and Omicron groups (73.1%) (<i>p</i> &lt; 0.001), probably due to the period of vaccine unavailability in the former group. Symptoms of fatigue and headache occurred most frequently, irrespective of infectious strain. The mean number of symptoms per patient was significantly higher in the Delta and before group than the Omicron group (3.4 vs. 2.7, <i>p</i> &lt; 0.0001). The median time overall to remission of long COVID was 169 days. Cox hazard model analysis identified female sex, high body mass index, and dyspnea (but not infectious strain) as significant factors prolonging the time to remission (<i>p</i> &lt; 0.05). <b>Conclusions:</b> Differences in the number of symptoms between infectious strains may be related to differences in viral virulence and/or vaccination coverage. However, the clinical course was found to be minimally influenced by the infectious strain. The present results should improve the understanding of prognosis in patients with long COVID from both the clinical and social perspectives.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baba</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Medical Center, Aichi Medical University, 17-33 Kawagoe, Niki-cho, Okazaki 444-2148, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawai</LastName><ForeName>Seiko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Medical Education, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute 480-1195, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwase</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Konan Kosei Hospital, 137 Omatsubara, Takaya-cho, Konan 483-8704, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ushida</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pain Relief Surgery &amp; Multidisciplinary Pain Center, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute 480-1195, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamura</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute 480-1195, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arimoto</LastName><ForeName>Mariko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute 480-1195, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nojiri</LastName><ForeName>Makiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Medical Center, Aichi Medical University, 17-33 Kawagoe, Niki-cho, Okazaki 444-2148, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6817-3993</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute 480-1195, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ban</LastName><ForeName>Nobutaro</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-6842-7455</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Medical Center, Aichi Medical University, 17-33 Kawagoe, Niki-cho, Okazaki 444-2148, Aichi, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Medical Education, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute 480-1195, Aichi, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID condition</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39274232</ArticleId><ArticleId IdType="pmc">PMC11396328</ArticleId><ArticleId IdType="doi">10.3390/jcm13175019</ArticleId><ArticleId IdType="pii">jcm13175019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Institute for Health and Care Excellence (NICE)  COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19. 2020 (published_guideline_6038-1_14)  [(accessed on 20 February 2021)].  Available online:  http://www.nice.org.uk/guidance/NG188.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Post COVID-19 Condition (Long COVID). 2021. Reference Number: WHO/2019-nCoV/Post COVID-19 Condition/Clinical Case Definition/2021.1.  [(accessed on 31 October 2021)]; Available online:  http://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition.</Citation></Reference><Reference><Citation>Antonelli M., Pujol J.C., Spector T.D., Ourselin S., Steves C.J. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263&#x2013;2264. doi: 10.1016/S0140-6736(22)00941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., Myles P., Williams T., Gokhale K.M., Taverner T., Chandan J.S., Brown K., Simms-Williams N., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 2022;8:1706&#x2013;1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q., Zheng B., Daines L., Sheikh A. Long-term sequelae of COVID-19: A systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens. 2022;11:269. doi: 10.3390/pathogens11020269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Choi T., Al-Aly Z. Postacute sequelae of SARS-CoV-2 infection in the pre-Delta, Delta, and Omicron eras. New Engl. J. Med. 2024;391:515&#x2013;525. doi: 10.1056/NEJMoa2403211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2403211</ArticleId><ArticleId IdType="pubmed">39018527</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahmer T., Borzikowsky C., Lieb W., Horn A., Krist L., Fricke J., Scheibenbogen C., Rabe K.F., Maetzler W., Maetzler C., et al. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study. EClinicalMedicine. 2022;51:101549. doi: 10.1016/j.eclinm.2022.101549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101549</ArticleId><ArticleId IdType="pmc">PMC9289961</ArticleId><ArticleId IdType="pubmed">35875815</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel S.A.M., Olde Hartman T.C., Lucassen P.L.B.J., van Jaarsveld C.H.M. Post-acute and long COVID-19 symptoms in patients with mild diseases: A systematic review. Fam. Pract. 2022;39:159&#x2013;567. doi: 10.1093/fampra/cmab076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmab076</ArticleId><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchida T., Yoshimura N., Ishizuka K., Katayama K., Inoue Y., Hirose M., Nakagama Y., Kido Y., Sugimori H., Matsuda T., et al. Five cluster classifications of long COVID and their background factors: A cross-sectional study in Japan. Clin. Exp. Med. 2023;23:3663&#x2013;3670. doi: 10.1007/s10238-023-01057-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-023-01057-6</ArticleId><ArticleId IdType="pmc">PMC10081305</ArticleId><ArticleId IdType="pubmed">37027067</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E., Altman D.G., Egger M., Pocock S.J., G&#xf8;tzsche P.C., Vandenbroucke J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J. Clin. Epidemiol. 2008;61:344&#x2013;349. doi: 10.1016/j.jclinepi.2007.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2007.11.008</ArticleId><ArticleId IdType="pubmed">18313558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health, Labour and Welfare, Japan  Japanese Outbreak Trend of COVID-19.  [(accessed on 1 September 2023)];2023  Available online:  http://www.mhlw.go.jp/content/10906000/001094012.pdf.</Citation></Reference><Reference><Citation>National Institute of Infectious Diseases, Japan  Detection of New Coronaviruses by Strain through Genome Surveillance.  [(accessed on 1 September 2023)]; Available online:  http://www.niid.go.jp/niid/images/cepr/covid-19/20221228_genome_surveillance.pdf.</Citation></Reference><Reference><Citation>Ministry of Health, Labour and Welfare, Japan  Manual of Medical Treatment for COVID-19 Ver.10.0.  [(accessed on 31 August 2023)]; Available online:  https://www.mhlw.go.jp/content/001136687.pdf. (In Japanese)</Citation></Reference><Reference><Citation>Ministry of Health, Labour and Welfare, Japan  Management of Post-COVID Condition Ver. 3.0.  [(accessed on 31 October 2023)]; Available online:  https://www.mhlw.go.jp/content/10900000/001159305.pdf. (In Japanese)</Citation></Reference><Reference><Citation>Fukuda S., Takashima S., Iwase M., Yamaguti K., Kuratsune H., Watanabe Y. Development and validation of a new fatigue scale for fatigued subjects with and without chronic fatigue syndrome. In: Watanabe Y., Eveng&#xe5;rd B., Natelson B.H., Jason L.A., Kuratsune H., editors. Fatigue Science for Human Health. Springer; Tokyo, Japan: 2008. pp. 89&#x2013;102.</Citation></Reference><Reference><Citation>Du M., Ma Y., Deng J., Liu M., Liu J. Comparison of long COVID-19 caused by different SARS-CoV-2 strains: A systematic review and meta-analysis. Int. J. Environ. Res. Public Health. 2022;19:16010. doi: 10.3390/ijerph192316010.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph192316010</ArticleId><ArticleId IdType="pmc">PMC9736973</ArticleId><ArticleId IdType="pubmed">36498103</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson K., Kristoffersen D.T., Dell&#x2019;Isola A., Kiadaliri A., Turkiewicz A., Runhaar J., Bierma-Zeinstra S., Englund M., Magnus P.M., Kinge J.M., et al. Post-COVID medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants. Nat Commun. 2022;13:7363. doi: 10.1038/s41467-022-35240-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35240-2</ArticleId><ArticleId IdType="pmc">PMC9709355</ArticleId><ArticleId IdType="pubmed">36450749</ArticleId></ArticleIdList></Reference><Reference><Citation>Maslo C., Friedland R., Toubkin M., Laubscher A., Akaloo T., Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. JAMA. 2022;327:583&#x2013;584. doi: 10.1001/jama.2021.24868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.24868</ArticleId><ArticleId IdType="pmc">PMC8719272</ArticleId><ArticleId IdType="pubmed">34967859</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren O., Stehlik P., Clark J., Alcorn K., Glasziou P. Effect of covid-19 vaccination on long covid: Systematic review. BMJ Med. 2023;2:e000385. doi: 10.1136/bmjmed-2022-000385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000385</ArticleId><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A., Iwagami M., Yasuhara J., Takagi H., Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine. 2023;41:1783&#x2013;1790. doi: 10.1016/j.vaccine.2023.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.02.008</ArticleId><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Vimercati L., De Maria L., Quarato M., Caputi A., Gesualdo L., Migliore G., Cavone D., Sponselli S., Pipoli A., Inchingolo F., et al. Association between long COVID and overweight/obesity. J. Clin. Med. 2021;10:4143. doi: 10.3390/jcm10184143.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10184143</ArticleId><ArticleId IdType="pmc">PMC8469321</ArticleId><ArticleId IdType="pubmed">34575251</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando W., Horii T., Uematsu T., Hanaki H., Atsuda K., Otori K. Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States. Sci. Rep. 2021;11:17968. doi: 10.1038/s41598-021-96720-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-96720-x</ArticleId><ArticleId IdType="pmc">PMC8429758</ArticleId><ArticleId IdType="pubmed">34504112</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosoya T., Oba S., Komiya Y., Kawata D., Kamiya M., Iwai H., Miyamoto S., Kataoka M., Tobiume M., Kanno T., et al. Apple-shaped obesity: A risky soil for cytokine-accelerated severity in COVID-19. Proc. Natl. Acad. Sci. USA. 2023;120:e2300155120. doi: 10.1073/pnas.2300155120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2300155120</ArticleId><ArticleId IdType="pmc">PMC10235975</ArticleId><ArticleId IdType="pubmed">37216518</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff A.L., Lipkin W.I. ME/CFS and long COVID share similar symptoms and biological abnormalities: Road map to the literature. Front. Med. 2023;10:118763. doi: 10.3389/fmed.2023.1187163.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1187163</ArticleId><ArticleId IdType="pmc">PMC10278546</ArticleId><ArticleId IdType="pubmed">37342500</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlaeyen J.W.S., Linton S.J. Fear-avoidance and its consequences in chronic musculoskeletal pain: A state of the art. Pain. 2000;85:317&#x2013;332. doi: 10.1016/S0304-3959(99)00242-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3959(99)00242-0</ArticleId><ArticleId IdType="pubmed">10781906</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>